Quantum BioPharma Ltd. (QNTM) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.63 (-2.42%), Market cap $0.05B, 52-week low–high $2.10 ~ $35.00.
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company's lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation
Financial statements, price targets, institutional (13F) holdings and related news for Quantum BioPharma Ltd. are updated in real time on BlackAll Trade.
Quantum BioPharma Ltd. trades at $3.63 (-2.42%). Real-time quotes and charts are available on BlackAll Trade.
Quantum BioPharma Ltd. has a market cap of about $0.05B.
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It r